DaVita Inc. (DVA) Earnings Call Transcript & Summary
October 28, 2021
Earnings Call Speaker Segments
Jim Gustafson
executiveThanks for joining us for this third quarter conference call, and we're glad you continue to follow our company. This is Jim Gustafson speaking, Vice President of Investor Relations, and with me today are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. I want to point out that on this call, forward-looking statements may be made by us as defined under federal securities laws. Known and unknown risks and uncertainties apply to each of these statements, and they could cause results in reality to differ materially from what the forward-looking statements describe. If you'd like more information about such risks and uncertainties, please see the earnings press release for our third quarter along with our SEC filings, which include our latest Annual Report on Form 10-K, our subsequent quarterly report on Form 10-Q, and any later filings we submit to the SEC. Information currently available to us serves as the basis for our forward-looking statements, and we have no intention, and take on no obligation, to update them, except where the law requires it. We'd also like to remind everyone that certain non-GAAP financial measures will be discussed on this call. You can find a reconciliation of those non-GAAP measures against the comparable GAAP financial measures in our earnings press release, which has been furnished to the SEC and is posted on our website. Javier Rodriguez will now take over the call.
Javier Rodriguez
executiveThank you, Jim, and good afternoon. DaVita delivered another robust quarter in Q3 despite a difficult operating climate. Even with yet another increase in COVID case numbers throughout the United States and a labor market that keeps getting tougher, we keep delivering quality care to our patients while carrying out our strategic objectives. Let me start my comments by calling attention to an exciting milestone: we have moved beyond 15% of our patients dialyzing at home. That translates to roughly 30,000 patients receiving the clinical and lifestyle advantages that home dialysis offers. Like we've mentioned before, to deliver home dialysis in a way that lasts, you need a full support system in place — one that gives people a handy, simple way to reach a home center for training and for ongoing appointments with our care team. Because our centers are already spread out the way they are, that kind of access is there today: 80% of our dialysis patients have a DaVita home center less than 10 miles from where they live. On top of that, we continue to roll out new ideas across our platform, both to make home dialysis a simpler option for patients and their physicians to pick, and to keep patients on home dialysis longer once they've picked it. Here are a few things worth pointing out. To start, we've just launched a stronger education offering, plus technology to back it up, so that people new to our care get modality instruction promptly and thoroughly, shaped around what each individual requires. Beyond that, we're still refining and tailoring how we educate various communities — including black and Hispanic patients — so more of them choose this modality, which moves us toward better health equity. And separately, we built a patient portal together with a telemedicine platform, enabling remote monitoring and conversations linking DaVita caregivers, our nephrologist partners, and patients at home. Third, we built a group of top-tier home physicians who form an expert network. This network collaborates closely with doctors in practice and their leaders, helping them grasp what home-based treatment approaches can offer, resolve tricky clinical problems, and raise their level of home clinical expertise. Finally, we are piloting artificial intelligence along with other tools to fine-tune PD prescriptions, giving doctors immediate notifications whenever a prescription update could be required. We'll go deeper into the strategic edge our platform provides during our Virtual Capital Markets Day on November 16. Now let's turn to our Q3 results. Even when operational hurdles arise, our business model keeps demonstrating its durability. During the third quarter, our operating income rose about 9% compared with a year earlier, while adjusted earnings per share climbed over 31% in that same span. Still, the COVID pandemic that hasn't gone away keeps causing loss of life for far too many people globally, including those we treat. Looking at the US as a whole, the wave fueled by the Delta variant looks like it hit its highest point in early September, when fresh case counts got to roughly two-thirds of the level seen at the previous winter's worst moment. On a positive note, among the patients we treat for dialysis, the number of new cases topped out at roughly one-third of the winner peak, and death rates were somewhat lower, probably because of how many of our patients have been vaccinated. Incremental mortality rose from under 500 in Q2 to about 2000 in Q3. Since the quarter closed, COVID infections have kept falling, and for the week that ended October 16, our new case count was down roughly 60% compared with the recent Delta peak. Turning to vaccines, about 73% of our patients are now vaccinated; beyond that, we have begun rolling out booster shots to eligible patients, following CDC guidelines. Looking ahead, we're optimistic that if COVID cases spike again or we see breakthrough infections, they'll be better contained than what we went through during the peak last winter. Turning to costs: our cost control held up well this quarter, despite the same labor-market pressures in healthcare that other companies have talked about. Even with those challenges, I'm pleased with how our frontline leadership has stepped up; being the employer of choice has long been central to our mission. How we live out that mission has been evident throughout the pandemic, because our team has stayed relentlessly focused on keeping patients safe and cared for, and on looking after one another too. As we've said on earlier calls, we keep offering a safe and rewarding workplace and have given extra pay and benefits to support our frontline caregivers through this tough period. Those efforts continue. In light of the current conditions, we anticipate giving our teammates larger annual compensation increases than we would in a typical year. That will add more strain on our cost structure, but we think it will help us draw in and keep the talent we need to reach our long-term goal. Equally important, it fits with our mission and continues our history of putting money into our people. Last, I want to make a few remarks about Integrated Kidney Care, or IKC. On the last earnings call, we shared details about how much we intend to put into IKS and the opportunity it opens up over the long run for patients, payers, and everyone who holds our stock. By the close of Q3, over 22,000 patients are now part of some form of integrated care arrangement, representing 1.7 billion in value-based care contracts. Looking ahead to next year, we anticipate our IKC business will grow to about twice its current size, largely driven by our involvement in the federal government's new cheap KCC program. Even though we're not far along and results hinge on how well we carry things out, we believe funding IKC could open up a fresh and possibly substantial profit avenue for the company across the coming years; we plan to explore that subject thoroughly during our Virtual Capital Markets Day, which is coming up soon. Having said that, I'll pass it to Joe, who will walk you through more details about the quarter.
Joel Ackerman
executiveAppreciate that, Javier. Even with the operational difficulties Javier brought up, we turned in yet another quarter of solid performance. Operating income came to $475 million, while earnings per share reached $2.36. Results for Q3 carry a net COVID headwind of roughly $55 million, which is larger than the quarterly effect we saw during the first half of the year. As Javier noted, the most recent COVID surge produced excess mortality of about 2000 during the quarter, versus fewer than 500 in Q2. We also expect mortality in Q4 to exceed what we saw in Q2, even though recent weeks have shown a decline that we're hoping will persist. Our present estimate of COVID's OI impact for the year is about $40 million worse than what we anticipated last quarter; for 2021, we now project a total net COVID impact of approximately $210 million. Treatments per day fell by 536, or 0.6%, in Q3 relative to q2. The main headwind came from the rise in our estimated excess mortalities and more mistreatment stemming from the COVID surge; on top of that, the quarter contained a greater proportion of Tuesdays, Thursdays and Saturdays, which reduced treatments per day by roughly 300 for the quarter; given the ongoing Delta surge, and how mortalities compound against our year-over-year growth, we now think the timing of a return to positive nag will be pushed into 2022. Revenue per treatment was basically flat versus the prior quarter, while patient care cost per treatment rose by about $5 quarter-over-quarter, largely driven by higher teammate compensation and benefit expenses. That reflects higher wages, added training costs tied to an increase in our new hires and seasonality in healthcare benefit expenses, which we expect to carry into Q4. Our Integrated Kidney Care business posted a smaller operating loss this quarter, mainly because of positive prior period development in our special needs plan. We still anticipate higher costs in Q4, particularly across our projected CKCC markets, as we build up staffing ahead of 2022. DSOs for our US dialysis and lab business rose by about three days quarter-over-quarter, mostly because of fluctuations in the timing of billing and collections. Other loss for the quarter was 7.6 million, primarily driven by a $9 million decline in the mark to market of our investment in Miromatrix. That investment was worth $14 million at quarter end; now shifting to some updates for the remainder of the year and beyond. As I said on the Q2 earnings call, we left out any effect from a significant COVID surge tied to the Delta variant in our revised guidance, but we noted a wider range of outcomes was possible depending in part on how a fourth surge would unfold. Now that the Delta surge's impact has become clear, we are raising our estimate of COVID impact for the year by $40 million. With the year already underway as it is, our updated adjusted OI outlook now reflects this COVID effect, landing at $1.76 billion to $1.81 billion. We're likewise tightening the adjusted EPS range to $8.80 to $9.15 per share. Free cash flow guidance stays at $1 billion to $1.2 billion, though it's possible we come in under the low end, depending on when our DSO recovery occurs. Compared with Q3, our revised OI guidance points to a weaker Q4. Part of that comes from the added COVID mortality impact, plus anticipated increases in salaries and wages for current frontline teammates. Our guidance bakes in roughly $75 million of seasonally high or one-time items hitting Q4 operating income, among them certain compensation expenses, elevated training costs, higher health benefit expenses, and G&A. Turning to 2022, the three headwinds I mentioned on the Q2 earnings call are still there. To recap, we expect added expense tied to the biggest share of the industry effort against the California ballot initiative. We anticipate a year-over-year incremental investment of about $15 million as our ITC business keeps growing; and we'll start depreciating our new clinical IP platform, which we expect to be roughly $40 million. A few more items to aid your thinking on 2022. COVID is still a major uncertainty. We're expecting the temporary sequestration suspension to end, which would create a $70 million headwind across the full year; we also expect certain costs that spiked during COVID, PPE especially, may take longer to come back to pre-COVID levels because of global supply chain difficulties. Lastly, how COVID affects mortality next year is still a big swing factor. Another winter surge would hurt treatment volume and might push back the timing of reaching positive NAG. If, on the other hand, the recent surge turns out to be the final significant COVID search, then we'd anticipate a tailwind from mortality running below typical levels, which could drive treatment growth above the pre-COVID level. In 2022, we expect net labor costs to rise more than they do in typical years because of market pressures. Our present estimate is a net headwind of $50 million to $75 million. We expect to offset a substantial portion of these incremental costs through continued MA penetration growth beyond historical levels, along with strong management of non-labor patient care costs. From an operating income growth standpoint, we expect 2022 to be a transition year, with some significant though largely temporary headwinds to work through, after which we expect our platform to keep supporting strong profit growth. Although the spectrum of possible 2022 results is wide, one sensible case might see operating income fall by $150 million relative to the guidance we gave for 2021; that figure accounts for the anticipated ballot initiative, IKC, and higher depreciation. A mild COVID-related drag is also baked into this case, even though some scenarios have COVID hitting considerably harder. Turning to 2023, we expect the net effect of those 2022 headwinds to reverse, alongside additional operating income growth, so that our 2023 operating income should deliver a low-to-mid single digit CAGR measured off the midpoint of the updated 2021 guidance we just provided, consistent with the multi-year outlook we've described in the past. We see this coming from the absence of ballot initiative-related costs, savings recognized in IKC, a better COVID backdrop, and ongoing expansion of the core business; we'll share more on long term guidance at our Capital Markets Day a couple of weeks from now. Lastly, in the third quarter we bought back 2.7 million shares of our stock, and in October so far, we've repurchased another 1.2 million shares. Operator, please open the call for Q&A.
Justin Lake
analystAppreciate it, and thanks for all the detail. Let's begin with Q4. From what you're saying, it sounds like the bulk of that 40 million in added COVID expenses is landing in the fourth quarter — is that right?
Javier Rodriguez
executiveLargely, yes, though a portion also hit Q3. So think of Q3 as 55 million, and if you subtract that from the COVID figure we provided for the entire year, roughly 85 million remains for Q4.
Justin Lake
analystAll right, and could you give us some insight into the mortality area — what exactly are you observing? Also, regarding that 40 million, how much of it — perhaps we even discussed the 75 million you mentioned that addresses a higher cost — how much of that stems from mortality?
Javier Rodriguez
executiveSure, so regarding mortality, what we've observed is an increase in Q3 to roughly 2000 excess mortality. Keep in mind, we were under 500 during Q2, and without question the Delta surge arrived larger than we anticipated. We also expect that to persist somewhat into Q4. So if you examine — if you're attempting to triangulate around growth, what you observe for the quarter, Q3 versus Q2, is treatment growth per day that's slightly lower, which is mostly due to the excess mortality; additionally, there were more Tuesdays, Thursdays, and Saturdays compared to Mondays, Wednesdays, and Fridays, and that represented roughly a 300 treatment per day headwind during the quarter too; so that's the — those are the figures underlying it. When it comes to the financial effect from COVID, what you're clearly seeing is the excess mortality that strikes in Q3, and it strikes even more severely in Q4. You're additionally seeing some rise in mistreatments, which we've observed during previous surges and we're expecting again in Q4, and then you also see some higher labor costs tied to cohorting and things of that nature; so that's how I would describe the influence of mortality and other factors on COVID in Q3 and Q4.
Justin Lake
analystAll right, and regarding that 75 million, does any portion of it — because it sounds like part of it is one time — so it's not really the implied Q4 OI. Would that be a sensible run rate, or is there, like, a step up from, or are there one-time costs inside that 75 million that push you off a larger base?
Javier Rodriguez
executiveYeah, so I'd view the 75 as arriving in two ways, either one-time or seasonal pickups. Regarding the nonrecurring pieces, I would mention certain compensation bonus items, plus training expenses increase as we add new team members, which usually leads to a larger training number; those, then, are the nonrecurring components within the 75, and beyond that there are certain seasonal elements. A seasonal benefit effect shows up in Q4, along with a seasonal rise in G&A. We generally observe these things in the majority of years, and this year they are somewhat amplified, because of the patterns that came out of COVID. When it comes to your core question about where a solid starting point for next year might be, my view is that the 2021 full-year figure works well as a baseline to launch from. If you were to take Q4 and make an adjustment for that 75 million, you'd land in roughly the same place.
Justin Lake
analystUnderstood. If there's room for one additional question — you extended your comments through 2023, and much of this appears reasonable when viewed as temporary expenses; however, you mentioned two components. IKC savings — you referenced 2022, where incremental losses might reach $50 million. With the favorable shift in '23, how much improvement should we expect from IKC? Then you brought up better COVID trends — could you size that benefit? That would be quite useful.
Javier Rodriguez
executiveCertainly. Let me begin with a caution: 2023 remains quite distant, and we're hesitant even to discuss '22 because of the uncertainty. So please don't treat this as guidance — just sensible approximations to assist your analysis. Regarding IKC, a $50 million reversal of the '22 headwind seems like a sensible assumption for '23. Essentially, finishing '23 roughly where we stood in '21. COVID is extremely difficult to forecast. That said, suppose COVID vanishes at some point during the coming year. Here's how I'd frame it — bridging from '21 to '23 — we have a $70 million sequestration suspension. That turns into a benefit. We received the full amount in '21; it vanishes in '22 and remains gone permanently, creating a $70 million obstacle. We also have a roughly similar figure for net COVID-related expenses. Consider labor, consider higher PPE spending, partially offset mainly by T&E, and that net figure stands at $70 million currently. As it fades, you effectively gain a benefit that counterbalances the sequestration obstacle, leaving mortality. Mortality currently, on a run-rate basis, sits around $240 million, and our expectation is that across a lengthy horizon — four, five, six, seven years — it declines to zero. So as that $240 million obstacle we face now diminishes, you'd see it return to earnings gradually. That covers the COVID situation.
Justin Lake
analystI appreciate that. Good, thanks.
Joel Ackerman
executiveLet me just tack on one more point, as you're wrapping up your bridge. Justin, keep in mind that a $60 million California ballot is coming in '22 — my mistake, right, that's '22, not '23. So you've got a couple more figures to factor into that bridge.
Justin Lake
analystThank you.
Joel Ackerman
executiveThank you. Okay, Michelle.
Kevin Fischbeck
analystGreat, thanks. I have one or two things to ask in response to what was just discussed. Regarding that figure for mortality, when you say it takes somewhere between 4 and 7 years to recover it, that strikes me as perhaps a longer stretch than I would have assumed for considering when that figure returns. In any case, why might it not be closer to 3 years instead of 4 to 7?
Javier Rodriguez
executiveYes. So Kevin, to begin with, you could be correct, and I believe there is probably a tail attached to it, correct. And how lengthy that tail is remains unknown to us, though there is definitely a quite plausible situation in which the majority of that rebound arrives — returns sooner, definitely sooner than 7 years and possibly sooner than 4 years. So it likely does not return uniformly across whichever number you pick, and I think there is sound reasoning to suggest you receive more during the early part of that stretch, while the tail becomes somewhat sparse near the conclusion; thus I would say you may be right about obtaining most of it within 3 years.
Kevin Fischbeck
analystAll right, that's useful. Then I believe you said that as a result of the COVID spike, NAG isn't expected to return to positive until next year. I can't recall — maybe you never said this — whether you'd previously thought it would happen by the end of the year?
Joel Ackerman
executiveShould we frame it this way: the most recent spike came in Q1, and at that point you figured you might return to positive by your year end, and now that a spike has arrived in Q3, perhaps three quarters afterward, we'll see positive NAG — is that the correct waiting period, or — Joel Ackerman: That's a reasonable starting point, I'd say. That said, how big the spike is also affects the amount of time required before NAG turns positive, since a smaller spike can be offset by natural growth more quickly. On earlier calls, as I've mentioned, I've come to see quarter-over-quarter treatment per day patterns as a far simpler lens for anticipating what will happen with our volumes and, in the end, revenue across the coming few years; NAG can be somewhat of an awkward figure during periods like this, when volatility is so high.
Kevin Fischbeck
analystAll right. Then for the final question, you brought up essentially making IKC twice as large. And I assume a significant chunk of that involves a government program — is there a way to separate out how you see growth in MA compared with the new program?
Javier Rodriguez
executiveAbsolutely. Well, at present, what we observe is that an increasing number of patients are examining their coverage and going with MA. So if you looked at the wider population, the most recent figure I came across in non-kidney was approximately 43% of patients picking MA, while our figure is now approaching that, sitting at about 41%. Consequently, as MA expands, naturally that should serve as a major pipeline into the risk side, since those plans approach us seeking contracts. When it comes to the government, we're at the last phases of determining the size of the practices that will actually sign up and thus attribute their patients, but our projections show both roughly doubling from our current level, and we'll share details once it unfolds.
Kevin Fischbeck
analystAll right. But then again, MA is essentially at penetration already. So the doubling comes just from shifting agreements you already hold with MA plans away from fee for service toward an IKC-type structure?
Javier Rodriguez
executiveYes. Right — so a greater number of plans are looking to adopt IKC-type structures, exactly.
Kevin Fischbeck
analystAll right, and now for my final question on this topic. Is there anything unusual here, or are these agreements coming together fast? Regarding when everything will fall into place, since this is year one, I can imagine plenty of organizations moving slowly. Would you anticipate that you'd mostly have captured that contract opportunity inside MA plans, or what share of your MA contracts would involve this kind of setup in the coming year? And when should we anticipate that most of them will be structured that way?
Javier Rodriguez
executiveYes, I'd say it varies depending on the payer, and it's fairly tailored, since as we're all aware, payers pursue distinct approaches and distinct timetables regarding where they direct their attention. Once more, the spectrum of agreements and frameworks spans everything from fee for service, paid to performance, gain shared, shared risk, right through to full risk, and it's essentially tailored per payer. So the timetable is genuinely tailored, we're prepared to move, and so we're in discussions with them, and there's nothing particularly noteworthy to share regarding timing as such; it's consistent and ongoing.
Kevin Fischbeck
analystAlright, so what you're saying is there won't be a big decline in the coming year — instead it's steady expansion, with membership climbing as you see it?
Javier Rodriguez
executiveOur projections don't include any dramatic shift.
Kevin Fischbeck
analystGot it. Thank you.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystYes. Hello, everyone, in the afternoon. As we begin the questions, I have one that builds on what Justin asked, and I apologize, since this call contains quite a few figures. Should you look at the middle point of the 2021 guidance, then apply a 4% CAGR to it, by 2023 you arrive at 1.93 billion in operating income. What portion of that originates from IKC as opposed to core dialysis, and in what way does IKC alter the low to mid single digit CAGR for OI moving forward?
Joel Ackerman
executiveYes, regarding what share of the OI in '23 is generated by IKC, once more, keeping in mind every one of the cautions regarding uncertainty and so forth, essentially no movement in OI and I KC will be visible from '21 to '23. That is, once more — that is a sensible scenario given where we stand. Thus, when you consider OI growth, overall OI growth from '21 to '23, in that scenario you essentially observe nothing coming from IKC.
Pito Chickering
analystAlright. So that roughly 4% OI growth for the CAGR across the coming 2 years — at this point, hundreds of that is originating from core dialysis. And even the -
Joel Ackerman
executivePito, I believe the proper way to frame this is that it's mostly originating from core dialysis. In that area, we've identified a number of headwinds and tailwinds; those tied to ballots and IKC essentially cancel one another out, meaning they net to zero. The depreciation associated with our new clinical IP system remains with us, and a tailwind from COVID is something you'll have.
Pito Chickering
analystAll right, though let me spend a moment running through those figures. If I use this year's OI once more, it includes $120 million in losses tied to IKC. Are you telling me that as of 2023, IKC will still be dragging $120 million in losses across the P&L?
Joel Ackerman
executiveCorrect. Essentially, our point is that 120 in 2021 rises to $170 million next year, which stands as one of the major headwinds we face in the coming year, and then in '23 that turns around.
Pito Chickering
analystAll right. So is it the entire 170 that gets reversed, or only 50 of them?
Joel Ackerman
executiveI'm asking whether it's just the — Joel Ackerman: No, only the 50.
Pito Chickering
analystAll right, I understand.
Joel Ackerman
executiveIn the end, what we'd expect is that the entire 150 reverses, and the business turns profitable, though that won't occur entirely within '23.
Pito Chickering
analystAll right. And when it comes to our labor side, as you begin to think through costs for treatment, how much of this is temporary, coming from premium labor, versus wage inflation, which is going to keep going in 2020? Could you remind us what your typical wage inflation was, and sort of what your thinking was for 3Q and 4Q?
Joel Ackerman
executiveYeah, so, in Q3 and Q4, there's a bit of wage inflation, but the place where that's truly going to begin showing up is next year, and I know I ran through a lot of numbers fast in the script. What we referred to at the start of the call as all doubt was a 50 million to 75 million net labor headwind next year, and that would be wages, it would be training, and there could be possible offsets from benefits or productivity and things like that; but I think the right number for next year, given the challenging labor environment, is a net headwind of 50 million to 75 million.
Pito Chickering
analystAlright, that's reasonable. When it comes to IKC, do you intend at some stage to break out the revenue and the cost on a per-patient basis, so we're better able to model how that's performing?
Joel Ackerman
executiveYes, I'd say we're moving along a route where we'll keep building out a disclosure package for IKC, which should provide shareholders with the transparency they require regarding how we're advancing.
Pito Chickering
analystAlright, and for my final question: at present, a billion dollars in cash is parked on the balance sheets—what amount of cash is required by you folks to operate the core dialysis business as well as the new IKC that's expanding in 2022? And at this juncture, how should we think about that cash going back toward this repo? Many thanks.
Joel Ackerman
executiveYeah, so I'd think about it as us generally requiring roughly $300 million of cash held on the balance sheet simply to keep the business running. My sense is that figure won't move meaningfully because of IKC—we aren't an entity subject to regulation, and statutory capital requirements don't apply to us.
Pito Chickering
analystAll right, it makes sense to consider that $300 million in surplus cash being available sooner rather than later.
Javier Rodriguez
executiveRegarding the $700 million in surplus cash, I would answer affirmatively. Obviously, we have been purchasing shares. Since the most recent earnings call, our buying has exceeded what we typically do. As stated previously, price matters to us. Should the price be appealing, we would purchase additional shares.
Pito Chickering
analystGreat, thank you very much.
Sarah James
analystThanks. I appreciate all the detail regarding '22 overall, but I'm hoping you can share a bit more about how the year will unfold. So those headwinds — do they begin early in the year, or come later? And on the labor cost front, we've heard some of the major players say labor costs will get better in the second half, and I just wasn't certain whether that's also what you're expecting in your guidance.
Javier Rodriguez
executiveSure. As for labor timing, I don't believe we hold a specific view regarding the macro economy and the labor market, or how that will unfold. So there's nothing I can add on that. IKC, I think much of that will begin early in the year — you'll actually see some of it in Q4 — but it definitely could accumulate as the year progresses. If the ballot initiative resembles what we've observed in the past, it mostly plays out in Q3, though there can be portions in other quarters. The depreciation figure I mentioned is probably more likely to be a second-half event; you might see a bit in Q2, but it will be weighted toward the back end. And COVID is complicated — the sequestration, assuming it disappears, will occur on 1/1, so there will be a significant impact tied to that beginning in January. How precisely the other costs unfold is difficult to forecast. Still, on balance, you'd likely see that getting better as the year continues, though it's not a particularly large number. And I'm not sure how to even assist you with the mortality figure. Historically, even when mortality declines, it still accumulates. Next year, if there's no winter wave and COVID generally starts to fade, I think you'd expect to see that beginning to improve as the year goes on. I hope that's helpful.
Sarah James
analystNo, that helps a lot. Thanks; and one final thing about labor. Could you share additional detail regarding where that pressure on labor shows up most sharply? Is it tied to a particular skill level or kind of role, and then how significant is that group of employees relative to your total FWD expenses?
Joel Ackerman
executiveSarah, I wish we could identify a single one, but the truth is, although it's sharper in some geographies, it's extremely broad and affects the majority of our clinical teammates, so it's extensive and spans many geographies.
Sarah James
analystGot it. Thank you very much.
Joel Ackerman
executiveThank you.
Lisa Clive
analystHello, I have a couple of items. First, regarding wage inflation, Medicare's rate updates clearly arrive with an unavoidable lag. Could you share details about the rate adjusters contained in your private contracts? Are they handled like Medicare, where they are fixed annually and rely on metrics that are somewhat backward-looking? My second item concerns integrated care, specifically the $120 million of losses still in 2023. I am attempting to grasp this and am really thinking about expanding that program. CKCC is clearly a significant factor. How large do you expect that program to become, and what would the ramp up resemble?
Javier Rodriguez
executiveI will take the first part, and then Joel can add. First, in case it helps, Medicare has a basket update, and its calculation does not examine pure dialysis and what is occurring with cost, whether retrospectively or prospectively. Instead, an economic firm provides an inflation forecast, and then they deduct what is termed a productivity adjustment, which essentially is a 10 year average attempting to gauge the economy's efficiency. So, as you might expect, that involves some complexity. When it comes to the commercial business, the approach is typically a negotiated one. Thus, each one is negotiated separately, and the timing is generally effective when the contract was signed. So, if you consider a contract signed in February, typically, the annual escalator would occur in February of the following year. That is the most traditional approach. Naturally, other methods exist that include pay for performance or other mechanisms. But generally, that is how it operates. Regarding your second question about CKCC, the short answer is we do not know; at present, it is a CMMI pilot, so it is authorized for two years. Naturally, the intent is to test it and see whether it is effective, whether it works for the system, and whether we are doing well by the patient, and then I would assume Medicare would then try to extend it. We try to imagine a world where hopefully, you reach somewhere in that 30,000 patients in one way or another, whether through MA or a CMMI vehicle, but we will see.
Lisa Clive
analystThanks for that.
Javier Rodriguez
executiveThank you, Lisa.
Pito Chickering
analystHi everybody, thank you — I have a question that builds on what we discussed. I want to go back to the IKC losses for 2023. It's a little hard for me to get my mind around the losses that you expect to see there. Back when the ESCO program was operating, savings showed up immediately. Why should we believe there will still be $120 million in IKC 3 years from now, if ESCO makes money for you? Many thanks.
Javier Rodriguez
executiveAll right, I'll start with the broader view, then Joel can walk through the figures. What matters about the ESCO isn't truly whether it made money — it's that the savings on the non-dialysis side are fairly strong. Yet obviously you need to put the operating model to work, and after that you need to add in the G&A. And under the model we have today, we must also share with partners, and that's how the number ends up coming down, and you need to get to scale. So one helpful frame is that once you've done all that and gone through each of those iterations, you'll likely end up with a low-single digit OI figure, and depending on whether you're capturing non-dialysis, I'd put it at roughly 3-ish percent or so; across the entire business, it lands at about 1.5%, because it's approximately half dialysis and half the other — the other non-dialysis costs. But when it came to the ESCOs, once they were fully loaded, we weren't earning anything; rather, the question people were asking was whether they succeeded in bringing non-dialysis costs down.
Joel Ackerman
executiveYeah, Pito, what I'd throw in there is — how would you describe the ultimate outcome, because the real question becomes how do you arrive at that point, and what I'd want to remind you of is that every bit of the expense hits early. The model of care has to be funded so those savings can be delivered, you're covering the G&A, you're developing capabilities, and the revenue shows up later; and in year one we'll see nothing, in year two we'll begin to see a bit, but that figure will keep expanding as the shared savings become more and more effective over time. So revenue and costs don't line up well at all, particularly during those early years. So one piece of it is putting money into the scale Javier mentioned, and another piece is the lag on the revenue side.
Pito Chickering
analystAll right, thank you.
Gary Taylor
analystHi there, good afternoon. I've got just 3 quick items, Joel — did you ever provide the sequential increase in depreciation on a quarterly basis that you've brought up on several occasions? I'm not sure I have that figure pinned down for the system as it stands now.
Joel Ackerman
executiveYes, the annualized figure comes to $40 million, Gary, and it will likely kick in at some point during Q2, though the bulk of it will show up across Q3 and Q4.
Gary Taylor
analystAlright, I'm just jotting that down. Then, is anything going on with — you mentioned a favorable commercial mix for two quarters straight? Beyond the Medicare mortality, is something else shifting that deserves a mention?
Joel Ackerman
executiveNo, I'd say throughout the pandemic there's been a strong recognition that folks wish to retain their coverage and they see its worth, so it has stayed quite steady and dependable.
Gary Taylor
analystUnderstood. For my final question, I want to revisit 2023 with you, Joel. Starting from 2021, we reduce it by 150 million, yet afterward we return to a low to mid single digit CAGR and move toward roughly one nine and change for 2023. That represents approximately a 300 million step up between '22 and '23. So the components would include an incremental 50 million from IKC, a 60 million decrease in advocacy spend, some low to mid single digit organic growth, and the remainder of that total would be a portion of this gross COVID mortality and direct expenses declining. Is that the main piece of it?
Joel Ackerman
executiveYou've got it exactly right.
Gary Taylor
analystAll right, that's great. Thanks very much.
Lisa Clive
analystHello, everyone. I just wanted to ask a bit more about the private contracting side. Regarding the way the rate increases are structured, if you've got, let's say, a contract lasting 4 years, are the rate adjustments across those 4 years locked in completely from the start, or could those adjustments go higher in the event that inflation runs hotter, which is obviously what you're seeing right now? Or are they simply set as a percentage increase for the duration of the contract?
Javier Rodriguez
executiveThe majority of them are fixed lease. With some of them, you have to earn your way to them, so depending on performance they can move up or down from one year to the next, but the majority are fixed.
Lisa Clive
analystAll right, though those would differ according to results, rather than what your base costs look like.
Javier Rodriguez
executiveThat's right. Naturally, at times you might have, say, something tied to an index or similar, but broadly speaking, it's set and clear.
Lisa Clive
analystOkay, that's clear. Thanks.
Javier Rodriguez
executiveThank you.
Javier Rodriguez
executiveAppreciate that, Michelle. Alright, we've gone through quite a bit, so allow me to pull it together as tidily as possible. Three key points: first, the fundamentals of our business remain solid; second, there are going to be many short-term OI declines in 2022 that will revert to historical OI levels come '23; and third, our teams are putting in serious effort around innovation so we can fulfill the integrated care dream. We're eager to share more specifics about our strategy on November 16 at our capital markets day, and we'll speak with you then. Take care, everybody.
Operator
operatorThanks. That wraps up the conference call for today. At this point, you're free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.